Introduction
Materials and methods
Search strategy and study screening
Inclusion and exclusion criteria
Methodological quality assessment
Data extraction
Data analysis
Results
Study characteristics
Authors (year of publication) | Study design (LOE) | Number of hips | L/R | No positive injection test | Age, years | M/F | BMI, kg/m2 | FU, months | Symptomatic period, months | Time period from THA to IP tenotomy, years |
---|---|---|---|---|---|---|---|---|---|---|
N° | N°/N° | N° | Mean ± SD (range) | N°/N° | Mean ± SD (range) | Mean ± SD (range) | Mean ± SD (range) | Mean ± SD (range) | ||
Williams et al. (2019) [23] | Prospective (IV) | 13 | 3/10 | 12 | 52.8 ± 13.7 (29.1–82.7) | 2/11 | 30.6 ± 8.5 | 24 (6–84) | 4 (2–24) | 2.9 ± 2.2 (0.4–10.1) |
Nikou et al. (2023) [29] | Retrospetive (IV) | 12 (13) | 8/5 | NR | 64.4 ± 15.1 | 4/8 | 26.6 ± 4.33 | 49.8 ± 25 | 9.3 ± 5.5 (0–52) | 3.5 (1.75–8.3) |
Tassinari et al. (2021) [30] | Retrospetive (III) | 16 | NR | All | 57.8 ± 11.1 | 5/11 | 26.1 ± 3.9 (19–33) | 27 ± 20.1 (6–48) | 12.8 ± 20.1 (1–80) | 3.4 (2–5) |
Jerosch et al. (2013) [2] | Retrospetive (IV) | 35 | NR | All | 58–82 | NR | NR | 43.2 (6–144) | NR | NR |
Di Benedetto et al. (2019) [31] | Retrospetive (IV) | 12 | NR | NR | 65 (47–82) | NR | NR | 10 (3–12) | NR | NR |
Bonano et al. (2022) [32] | Retrospetive (IV) | 28 | NR | 20 | 69 (62.8–74.3) | 8/20 | 30.4 (25.2–34.3) | 7.6 (1–28) | NR | 2.7 (1.5–6) |
Amellal et al. (2020) [33] | Retrospetive (III) | 19 | NR | All | 66 ± 11 (36–88) | 9/10 | 28.1 ± 5.6 (21–43) | 36 (6–66) | NR | 4 (0.5–7.3) |
Guicherd et al. (2017) [34] | Prospective (IV) | 64 | NR | 48 | 56.3 (33–78) | 24/40 | 26.0 (18.4–37.7) | 8 | 40.3 (4–144) | NR |
Finsterwald et al. (2023) [35] | Retrospetive (IV) | 36 | NR | 31 | 62 ± 12 (27–83) | 11/26 | 28.9 ± 4.3 (23.2–38.5) | 24 | NR | NR |
Viamont-Guerra et al. (2021) [36] | Retrospetive (IV) | 48(50) | NR | NR | 60.8 ± 10.5 (35.5–80.3) | 16/32 | 26.2 ± 4.8 (18.2–39.2) | 31 ± 15 (12.3–71.5) | 38.1 ± 29.9 (2–132) | NR |
Valenzuela et al. (2021) [37] | Retrospetive (IV) | 35 | 12/23 | All | 62 ± 10.33 (40–84) | 15/20 | 28.74 ± 4.94 (20.3–41.1) | LT: 49.11 ± 20.46 AR: 42.42 ± 12.25 | LT: 3.2 ± 5.42 AR: 4 ± 5.9 | NR |
Bell et al. (2019) [38] | Retrospetive (IV) | 60 | 29/31 | 55 | 62.5 ± 9.7 | 24/36 | 29.6 ± 5.7 | 6 | 26.8 | NR |
Moreta et al. (2021) [39] | Retrospetive (III) | 12 | NR | All | 59.1 (40–72) | 6/6 | 27.2 (21.3–31.5) | 45 (24–96) | 12 (6–18) | 1.7 (0.7–2.2) |
Zimmerer et al. (2022) [40] | Retrospetive (IV) | 20 | 8/12 | All | 59 ± 27.7 (52–78) | 10/10 | 25.7 ± 5.5 (20.4–34.5) | 7 ± 3.8 (2.6–11.7) | NR | 6.3 ± 4.0 (1.7–15) |
Gédouin et al. (2012) [41] | Retrospetive (IV) | 10 | NR | NR | 58 (45–80) | 5/5 | NR | 20 (12–60) | 43 (14–72) | NR |
Filanti et al. (2016) [42] | Retrospetive (IV) | 11 | NR | NR | 57 (29–77) | 6/5 | NR | 24 | 10.8 (5–15) | NR |
Demographics
Authors (year of publication) | Characteristics of hip prosthesis | Cup frontal inclination (◦) | Cup anterior overhang (mm) | Cup anteversion (◦) |
---|---|---|---|---|
N° | Mean ± SD (range) | Mean ± SD (range) | Mean ± SD (range) | |
Williams et al. (2019) [23] | 2 Cemented THA, 11 Cementless THA | NR | NR | NR |
Nikou et al. (2023) [29] | 7 Cemented THA, 4 Cementless THA, 2 Hybrid THA | 44.6 ± 6.9 (31–51) | 8.71 ± 4.5 (1–14) | 18.7 ± 6.8 (11–37) |
Tassinari et al. (2021) [30] | 16 Cementless THA | NR | 13 ± 4.8 (5–20) | NR |
Jerosch et al. (2013) [2] | 35 THA | NR | NR | NR |
Di Benedetto et al. (2019) [31] | 11 THA, 1 Endoprosthesis, 1 Resurfacing | NR | NR | NR |
Bonano et al. (2022) [32] | 28 THA | 45 (37.8–49) | 7.0 (2.3–12) | 30 (24.5–38) |
Amellal et al. (2020) [33] | 15 Primary THA, 1 Revision THA, 3 Resurfacing | 45.7 ± 4.8 | 5.9 ± 2.8 | 12.3 ± 4.9 |
Guicherd et al. (2017) [34] | 64 THA | 44.8 (35–60) | NR | 17.6 (0–38) |
Finsterwald et al. (2023) [35] | 21 Primary THA, 12 Revision THA, 3 Resurfacing | 42.5 ± 7.2 (40–44.9) | NR | 18.3 ± 9.5 (15.0–21.6) |
Viamont-Guerra et al. (2021) [36] | 42 Primary THA, 8 Revision THA | 46.1 ± 7 (25–60) | 6.9 ± 5.0 (0–20.5) | 15.0 ± 8.6 (0–31.6) |
Valenzuela et al. (2021) [37] | 33 THA | NR | NR | NR |
Bell et al. (2019) [38] | 60 THA | 44.1 ± 6.6 | 3.2 ± 6.7 | 13.4 ± 8.8 |
Moreta et al. (2021) [39] | 12 THA | NR | 7.25 (3–12) | NR |
Zimmerer et al. (2022) [40] | 20 Cementless THA | NR | 5.5 ± 1.8 (2–8) | NR |
Gédouin et al. (2012) [41] | 9 THA, 1 Resurfacing | NR | NR | NR |
Filanti et al. (2016) [42] | 9 Primary THA, 2 Resurfacing | NR | NR | NR |
Procedures performed
Authors (year of publication) | Anesthesia | Surgical technique | Post operative rehabilitation |
---|---|---|---|
Williams et al. (2019) [23] | Spinal | Endoscopic extraarticular tendon release (1–2 cm from LT) ± distal tendon stump (1 cm) removal | Full WB with crutches with hip extension/stretching exercises and hip flexion/strengthening exercises |
Nikou et al. (2023) [29] | General | Arthroscopic tendon released at acetabular cup | Full WB with crutches for first days, physical therapy immediately |
Tassinari et al. (2021) [30] | General | Arthroscopic transcapsular tenotomy until the muscular IP fibers | Full ROM and WB (with crutches) Capsular and iliopsoas stretching exercises |
Jerosch et al. (2013) [2] | General | Arthroscopic tenotomy of the tendinous part | Patients according to their pain allowed to fully WB |
Di Benedetto et al. (2019) [31] | NR | Arthroscopic tendon release at anterior rim of acetabular cup (one patient ossification excision) | No WB and assisted rehabilitation with passive ROM for 2 weeks Avoid active hip flexion with straight leg raise for 4 weeks |
Bonano et al. (2022) [32] | NR | Endoscopic tenotomy at LT | Protected WB and no resisted hip flexion of 6 weeks |
Viamont-Guerra et al. (2021) [33] | NR | Endoscopic IP tenotomy at the level between LT and the psoas valley on the acetabular rim | Full WB allowed as tolerated, cryotherapy started immediately with iliopsoas stretching, psoas strengthening started after 1 month |
Amellal et al. (2020) [34] | General | Endoscopic tenotomy at LT | Full WB was immediately allowed Iliopsoas stretching, muscle strengthening |
Guicherd et al. (2017) [35] | NR | Endoscopic tenotomy at LT: 57 hips Arthroscopic transcapsular tenotomy: 7 hips | Post–operative physiotherapy prescribed for 44% of patients |
Finsterwald et al. (2023) [36] | NR | Endoscopic tenotomy at LT | Full WB with or without the use of crutches Avoid repetitive and resisted hip flexion first 6 weeks |
Valenzuela et al. (2021) [37] | NR | Endoscopic tenotomy at LT: 21 hips Arthroscopic tenotomy at acetabulum rim: 14 hips | Full WB as tolerated, physiotherapy first 2 weeks keep hip flexion under 90, hip flexion and stretching exercises after 6 weeks |
Bell et al. (2019) [38] | NR | Endoscopic tenotomy at LT | Protected WB for 2 weeks and resisted hip flexion for 6 weeks |
Moreta et al. (2021) [39] | NR | Arthroscopic tenotomy at the edge of the acetabular | Full ROM and WB allowed with stretching exercises of iliopsoas Strengthening hip flexion exercises delayed for 3 months |
Zimmerer et al. (2022) [40] | General | Arthroscopic transcapsular tenotomy | First 2 weeks, hip flexion and WB with crutches After 2 weeks strengthening abductors and core muscles |
Gédouin et al. (2012) [41] | NR | Endoscopic extra–articular tenotomy | Full WB allowed, with two canes for support for 3 weeks |
Filanti et al. (2016) [42] | NR | Arthroscopic transcapsular tenotomy | Full ROM allowed immediately with capsular and iliopsoas stretching Partial WB using crutches for 2 weeks |
Endoscopic iliopsoas tenotomy
Arthroscopic iliopsoas tenotomy
Outcome data
Authors (year of publication) | Pre op outcome; mean (range) | Post op outcome; mean (range) | Recurrence | Revision | Complications | Surgical technique | Successful Outcome |
---|---|---|---|---|---|---|---|
N° | N° | N° | N°/ N° (%) | ||||
Williams et al. (2019) [23] | FABER test: all positive | FABER test: N°:9 negative, N°:2 positive, N°:2 unable | 1 | 1 | 5 (mild pain) | Endoscopic | 8/13 (62%) |
Nikou et al. (2023) [29] | iHOT-12a*: 24.9 ± 13.8 HAGOS symptoms*: 38.2 ± 17.6 HAGOS-pain*: 36 ± 18.3 HAGOS-sport*: 14.1 ± 10.4 HAGOS-daily activity*: 31 ± 23.5 HAGOS-physical activity*: 21.8 ± 22.5 HAGOS- quality of life*: 24 ± 10.7 EQ-5D*: 0.339 ± 0.368 EQ-VAS*: 57.9 ± 15.9 | iHOT-12a*: 39.5 ± 19.6 HAGOS symptoms*: 54.5 ± 33.1 HAGOS-pain*: 53 ± 30.3 HAGOS-sport*: 35.1 ± 22.1 HAGOS-daily activity*: 47.5 ± 28.6 HAGOS-physical activity*: 24 ± 21.9 HAGOS- quality of life*: 35 ± 20.9 EQ-5D*: 0.127 ± 0.385 EQ-VAS*: 58 ± 22.4 | 0 | 0 | 2 (mild pain) | Arthroscopic | 10/12 (83%) |
Tassinari et al. (2021) [30] | WOMAC*: 36.1 ± 8.6 (28–44) | WOMAC*: 83.4 ± 9.5 | 1 | 1 | 2 (mild pain) | Arthroscopic | 13/16 (81.3%) |
Jerosch et al. (2013) [2] | Presence of pain | Elimination of pain: 33/35 | 0 | 0 | 2 (mild pain) | Arthroscopic | 33/35 (94%) |
Di Benedetto et al. (2019) [31] | HHS*: 66.8 (48.9–81.8) MRC scale*: 3.6 (3–4) Hip flexion*: 95° (80°-100°) VAS*: 3.6 (2–6) | HHS*: 85 (80–95) MRC scale*: 4.7 (3–5) Hip flexion*: 105° (90°-120°) VAS*: 1 (0–3) | 0 | 0 | 0 | Arthroscopic | 100% |
Bonano et al. (2022) [32] | mHHS*: 57 (43–60) | mHHS*: 75 (66–92) VAS*: 3 (0.8–5) iHOT-12*: 71 (48–80) | 1 | 1 | 2 (infection) | Endoscopic | 17/28 (71%) |
Amellal et al. (2020) [33] | VAS*: 6.15 ± 1.16 (4–8) OHS*: 25.2 ± 6.4 | VAS*: 2.4 ± 2.6 (0–7) OHS*: 38.02 ± 12 | 4 | 0 | 3 (Hematoma) | Endoscopic | 15/19 (79%) |
Guicherd et al. (2017) [34] | OHS*: 21.8 Strength differential (MRC)*: − 1.7 | OHS*: 40 Strength differential (MRC)*: − 0.7 | 0 | 0 | 1 (dislocation) 1 (hematoma) | Endoscopic:57 hips; Arthroscopic: 7 hips | 94% |
Finsterwald et al. (2023) [35] | mHHS*: 59.0 ± 19.5 (18.7—94.6) VAS*: 5.7 ± 1.7 (2.9–9) SANE-hip*: 54.3 ± 22.6 (1–91) | mHHS*: 82.9 ± 11.9 (61.6—100) VAS*: 2.1 ± 2.1 (0–7) SANE-hip*: 75.7 ± 17.1 (40–100) | 0 | 0 | 1 (pain) | Endoscopic | 97.2% |
Viamont-Guerra et al. (2021) [36] | mHHS*: 57.7: ± 11.5 (31.9–81.4) OHS*: 29.4 ± 11 (4.-50) | mHHS*: 83.2 ± 16.9 (0–100.1) OHS*: 50.5 ± 8.4 (28.-60) | 0 | 0 | 0 | Endoscopic | 40/50 (86.9%) |
Valenzuela et al. (2021) [37] | VAS LT*: 5.32 ± 1.06 AR*: 5.75 ± 1.29 | VAS LT*: 51.75 ± 1.77 AR*: 2.62 ± 2.22 mHHS LT*: 88.98 ± 10.29 AR*: 81.05 ± 12.44 NASH LT*: 85.99 ± 11.11 AR*: 78.85 ± 10.10 | 0 | 0 | 0 | Endoscopic: 21 hips; Arthroscopic: 14 hips | (70.58%) |
Bell et al. (2019) [38] | HOS(ADL)*: 57.5 ± 18.8 (10.9–89.3) HOS sports*: 37.3 ± 24 (0–83.3) | HOS(ADL)*: 71.6 ± 26.1 (14.1–100) HOS sports*: 58.1 ± 33.2 (0–100) | 4 | 0 | 1 (asepting loosening) 1 (post-operative fall) 1 (hematoma) 1 (CRPS) | Endoscopic | 56/60 (93.3%) |
Moreta et al. (2021) [39] | VAS*: 6.2 (4–8) HHS*: 58.8 (37–76) | VAS*: 1.08 (4–8) HHS*: 86.1 (59–98) MRC scale*: 4.58 (4–5) | 0 | 0 | 1 (mild pain) | Arthroscopic | 11/12 (91.7%) |
Zimmerer et al. (2022) [40] | mHHS*: 31.2 ± 9.8 (17.6–47.3) VAS*: 8.5 ± 1.2 (7–10) UCLA Score*: 4.0 ± 2.7 (0–7) | mHHS*: 82.0 ± 9.8 (46.2–100) VAS*: 2.5 ± 1.8 (0–6) UCLA Score*: 6.5 ± 1.8 (3–9) | 0 | 0 | 2 (mild pain) | Arthroscopic | 18/20 (90%) |
Gédouin et al. (2012) [41] | PMA*: 13.1 (11–15) WOMAC*: 34 (24–46) | PMA*: 16.9 (15–18) WOMAC*: 84 (60–95) | 2 | 0 | 0 | Endoscopic | 8/10 (80%) |
Filanti et al. (2016) [42] | HHS score*: 46.4 (32–56) MRC scale*: 3.27 (3–4) | HHS score*: 83.3 (61–91) MRC scale*: 4.45 | 1 | 0 | 0 | Arthroscopic | 10/11 (86%) |